Assured AstraZeneca will offer ADC to FDA, despite data doubts

28 July 2023

AstraZeneca (LSE: AZN) has reported total revenues of $11.4 billion in the second quarter of 2023, a rise of around 6%, beating expectations from most analysts.

On a reported basis, the earnings per share (EPS) figure hit $1.17, with sales in oncology and cardiovascular and renal medicine rising 22% and 20%, respectively.

The company’s newly-enlarged interest in rare diseases, following the acquisition of Alexion, continues to perform well, growing 12% in the quarter.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK